Sign in
KOD Stock Price, Chart, Stats & News
Kodiak Sciences Inc.
Save
Kodiak Sciences Inc. (KOD) does not currently pay a dividend.
2.02B
Market cap
–
Current P/E
–
Forward P/E
KOD chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -99.66% |
ROE | -246.19% |
D/E | 2.63x |
Interest coverage ratio | – |
KOD valuation
P/E | – |
P/S | – |
P/B | 82.55x |
P/CF | -15.44x |
P/FCF | -15.39x |
P/OCF | -15.44x |
PEG | 1.07x |
EV multiple | -10.31x |
About
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy.
Similar securities
Based on sector and market capitalization
Report issue